Abstracts Archive - Page 17 of 2605 - ACR Meeting Abstracts

Abstract Number: 0086 • ACR Convergence 2025
Androgen Upregulates Interferon Signaling in Osteoclast Differentiation During Inflammatory State
Kiana Chen¹, Chia-Lung Wu², Gulzada Kulzhanova² and Homaira Rahimi³, ¹University of Rochester School of Medicine and Dentistry, Bronx, NY, ²University of Rochester Medical Center, Rochester, ³University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is characterized by chronic inflammatory erosions and female predominant disease. Androgen, the dominant sex hormone in males, is protective against bone…
Abstract Number: 0072 • ACR Convergence 2025
Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs
Chary López pedrera¹, Laura muñoz-Barrera², Rafaela Ortega-Castro³, Sagrario Corrales², Jerusalen Calvo Gutierrez⁴, Concepción Aranda Valera⁵, Lourdes Ladehesa⁶, Pilar Font⁷, Ismael Sanchez-Pareja², Elena Moreno-Caño⁵, M Carmen Abalos-Aguilera⁸, Christian Merlo-Ruiz⁸, MARIA ANGELES AGUIRRE ZAMORANO², Pedro Seguí-Azpilcueta⁹, Tomás Cerdó², Nuria Barbarroja¹⁰, Rocío González Conejero¹¹, Constantino Martínez¹¹, Carlos Pérez Sánchez¹² and Alejandro Escudero¹³, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Sevilla, Spain, ⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁶IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁹Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Servicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB Pascual Parrilla., Murcia, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Andalucia, Spain
Background/Purpose: Therapeutic advances in RA have introduced effective treatments, including b/tsDMARDs such as Baricitinib. However, its cardiovascular safety profile remains unclear, partly due to the…
Abstract Number: 0069 • ACR Convergence 2025
Spatial transcriptomics in rheumatoid arthritis (RA) synovium reveals distinct region-specific fibroblast functions
Camilla R.L. Machado¹, Mina Yao¹, David Boyle², Robert J. Benschop³, James T. Parker³, Wei Wang² and Gary Firestein¹, ¹University of California, San Diego, San Diego, CA, ²University of California, San Diego, San Diego, ³Eli Lilly, San Diego
Background/Purpose: RA synovium displays cellular heterogeneity, with gene expression driving disease pathogenesis. Unbiased cell-specific transcriptomes in RA synovium have previously relied primarily on disaggregated tissues…
Abstract Number: 0065 • ACR Convergence 2025
Expression and Co-Localization of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues Precedes the Development of Cardiac Fibrosis in Collagen-Induced Arthritis
Wenxian Zhou¹, Hannah Johnson², Michael Duryee², Ali Namvaran³, Julian Garcia², Carlos Hunter², Tate Johnson², Daniel Anderson⁴, Kishore Bidasee², Geoffrey Thiele² and Ted Mikuls², ¹University of Nebraska Medical Center, Bellevue, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, ^40587964, Durham, NC
Background/Purpose: Patients with rheumatoid arthritis (RA) experience increased morbidity and mortality due to heart failure with preserved ejection fraction (HFpEF), a condition characterized by diastolic…
Abstract Number: 0051 • ACR Convergence 2025
Spp1+ Macrophages Are Specifically Enriched in Arthritic Joints and Associated with Abnormal Bone Metabolism in Collagen-Induced Arthritis Mice
Chenjia He, Xuyang Xia, Heng Xu, Geng Yin and Qibing Xie, West China Hospital, Sichuan University, Chengdu, China (People's Republic)
Background/Purpose: Synovial fluid (SF) of RA patients contains unique SPP1+ macrophages that drive pathogenesis by activating fibroblast-like synoviocytes (FLS). Single-cell RNA sequencing (scRNA-seq) data from…
Abstract Number: 0057 • ACR Convergence 2025
TNF Inhibition with Small-molecule Agents Results in Amelioration of Inflammation Similar to that of Anti-TNF Biologics While Preserving TNFR2 Signaling and Maintaining a Suppressive Regulatory T cell Phenotype
Rajesh Singh¹, Bindi Patel², Rameshwari Rayaji², Archana Sidalaghatta Nagaraja², Saranya Chandrasekar², Yihong Guan², Ritu Kushwaha², Yue Tong Lee², Cesar Meleza², Matthew Epplin², Brandon Rosen², Manmohan R Leleti², Matthew J Walters² and Daniel DiRenzo², ¹Arcus Biosciences, inc., Santa Clara, CA, ²Arcus Biosciences, inc., Hayward, CA
Background/Purpose: Anti-TNF biologics are effective in the treatment of inflammatory diseases such as rheumatoid arthritis and psoriasis. However, they can lead to de novo inflammation…
Abstract Number: 0054 • ACR Convergence 2025
Microbial Cues Promote Arthritis and Alter T Cell Selection in SKG Mice
Astha Patel¹, Steven yu¹, Yuka Nakao¹, Mohana Mukherjee¹, Diego Orellana², Jose Scher³, Peter Turnbaugh¹, Renuka Nayak⁴ and Judith Ashouri¹, ¹University of California, San Francisco, San Francisco, CA, ²University of California San Francisco, San Francisco, CA, ³New York University School of Medicine, New York, NY, ⁴University of California, San Francisco (UCSF), San Francisco, CA
Background/Purpose: Dysbiosis of the gut microbiota has been linked to rheumatoid arthritis (RA), but it remains unclear whether these microbial alterations are causal or secondary…
Abstract Number: 0050 • ACR Convergence 2025
TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
Preeyam Patel¹, Matthew Siegel², Emily Lewis³, David Giles³, Justin LaFountaine³, Joshua Friedman³ and Andy Spencer³, ¹Spyre Therapeutics, Waltham, ²Spyre Therapeutics, Menlo Park, CA, ³Spyre Therapeutics, Waltham, MA
Background/Purpose: The development of disease-modifying anti-rheumatic drugs (DMARDs) has reduced disease activity in patients living with rheumatic diseases. Despite this, there is continued unmet need…
Abstract Number: 0106 • ACR Convergence 2025
Investigation of DNA Methylation Inhibition in a Mouse Model of Ankylosing Spondylitis
Goh Murayama¹, Kurisu Tada², Naoto Tamura³, Eri Hayashi¹, Taiga Kuga⁴, Ken Yamaji⁵ and HOSHIKO FURUSAWA⁶, ¹Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University Graduate School of Medicine, Tokyo, ³Juntendo University School of Medicine, Tokyo, Japan, ⁴Juntendo University, Tokyo, Japan, ⁵Juntendo University, Department of Internal Medicine and Rheumatology, Tokyo, Japan, ⁶juntendo, tokyo, Japan
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by enthesitis in axial joints, bone erosion near the entheses, and subsequent irreversible ankylosis due…
Abstract Number: 0251 • ACR Convergence 2025
Impact of Mepolizumab on Idiopathic Hypereosinophilic Syndromes: Preliminary Analysis of a Monocentric Retrospective Cohort
Jacopo Mora¹, Francesca Regola¹, Paola Toniati², Giulia Fontana¹, Alessia Gatti¹, Ilaria Cavazzana³ and Franco Franceschini⁴, ¹Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili and University of Brescia, Brescia, Lombardia, Italy, ²Rheumatology and Clinical Immunology Unit – ERN ReCONNET, ASST Spedali Civili of Brescia, Brescia, Lombardia, Italy, ³Rheumatology and Clinical Immunology Unit, Clinical and Experimental Sciences Department, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Brescia, Italy, Brescia, Lombardia, Italy, ⁴University of Brescia, Brescia, Brescia, Italy
Background/Purpose: Idiopathic hypereosinophilic syndromes (iHES) are a group of disorders characterized by persistent eosinophilia and eosinophil-mediated organ damage. Mepolizumab, an anti-interleukin-5 monoclonal antibody, has proven…
Abstract Number: 0024 • ACR Convergence 2025
Biobank-scale genetic mapping identifies the shared genetic landscape of rheumatic and cardiovascular disease
Daniel Panyard¹, Daniel Li², Pik Fang Kho², Rodrigo Guarischi-Sousa³, Jiayan Zhou², Austin Hilliard⁴, Christie Bartels⁵, Philip Tsao² and Themistocles Assimes², ¹Stanford University, Sunnyvale, CA, ²Stanford University, Palo Alto, CA, ³Palo Alto Veterans Institute for Research, Palo Alto, CA, ⁴VA Palo Alto Health Care, Palo Alto, CA, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients with rheumatic conditions are at increased risk for cardiovascular (CV) problems, striking on average a decade before peers and conferring substantial morbidity and…
Abstract Number: 0244 • ACR Convergence 2025
Effectiveness and safety of Anifrolumab in Non-Systemic Cutaneous Lupus
Carmen Lasa Teja¹, Javier Loricera², Marcos López-Hoyos³, Carmen Bejerano-Herreria⁴, Andrea Estébanez⁵, Mireia Sanmartin Martínez⁶, Marta González-Fernández⁷, Ivan Ferraz Amaro⁸ and Ricardo Blanco⁹, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁵Department of Dermatology, Hospital Universitario Doctor Peset, Valencia, Spain, Valencia, Spain, ⁶Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ⁷Basurto University Hospital, Bilbao, Pais Vasco, Spain, ⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Anifrolumab is a human monoclonal antibody targeting the type I interferon receptor, approved for the treatment of systemic lupus erythematosus (SLE), with demonstrated efficacy…
Abstract Number: 0018 • ACR Convergence 2025
Development of a noval ‘1+1+1’ CD19- and BCMA-dual targeted T cell engager for autoimmune diseases
Lin Huan, Hao Ran, Shiyi Wang, Xiaoping Zhang, Bing Yang, Yang He, Dandan Liu, Chenpeng Su, Chuan Chen, Xiaoqian Chen, Kezhen Ye, Liang Tian, Jian Peng and Zhenping Zhu, Helixon Therapeutics, New York
Background/Purpose: B cells and autoantibodies play a central role in the pathogenesis of various autoimmune diseases. Although CD19-targeted B cell depletion shows promising therapeutic potential,…
Abstract Number: 0090 • ACR Convergence 2025
Interleukin-36β modulates the progression of rheumatoid arthritis by altering the behavior of rheumatoid arthritis synovial fibroblasts
Marie Svenja Kümmel¹, Mona Arnold-Gräf², Selina Ohl², Klaus Frommer³, Nils Schulz⁴, Stefan Rehart⁵, Ulf Müller-Ladner³ and Elena Neumann³, ¹Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Justus-Liebig-University, Germany, Gießen, Germany, ²Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Justus-Liebig-University, Germany, Bad Nauheim, Germany, ³Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Justus-Liebig-University, Germany, Bad Nauheim, Hessen, Germany, ⁴Kerkchoff Klinik, Dep. of rheumatology, Bad Nauheim, Germany, ⁵Agaplesion Markus Hospital, Frankfurt, Hessen, Germany
Background/Purpose: Rheumatoid arthritis synovial fibroblasts (RASF) play a central role in driving inflammation and promoting cartilage degradation in Rheumatoid arthritis (RA). In our study, we…
Abstract Number: 0093 • ACR Convergence 2025
Soluble CD13 engages protease-activated receptor 4 to promote synovial inflammation and angiogenesis in rheumatoid arthritis
Chenyang Lu¹, Megan N Mattichak², Simin Xu¹, William D Brodie³, Neha Khanna², Hafsa Amin², Qi Wu², Phillip Campbell², David Fox⁴ and Pei-Suen Tsou⁵, ¹Division of Rheumatology, Department of Internal Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Guangzhou, China (People's Republic), ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, ⁴University of Michigan, Dexter, MI, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Soluble CD13 (sCD13), the soluble form of aminopeptidase N/CD13, exhibits potent chemoattractant, angiogenic, and arthritogenic properties. While we previously identified certain G protein-coupled receptors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].